세계의 유방 생검 기기 시장 : 제품별, 시술별, 용도별, 최종사용자별 - 예측(-2030년)

The global market for breast biopsy devices is expected to reach USD 3,261.7 million by 2030 from USD 2,384.1 million in 2025, representing a CAGR of 6.5% during the forecast period. The market is benefiting from a combination of factors, including rising breast cancer rates, increased awareness of the importance of early detection, and the growing preference for minimally invasive diagnostic procedures. Additionally, state and provincial screening programs are significantly improving the rate of screenings among women for potential breast cancer.

The biopsy needles segment held the largest share of the market in 2024.

Based on type, the breast biopsy devices market is divided into several segments: biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and other devices. Among these, the biopsy needles segment holds a significant share of the market. Biopsy needles are essential tools for diagnosing breast cancer, as they collect tissue samples for histopathological analysis with high accuracy and minimal invasiveness. They can be utilized in core-needle biopsy (CNB), fine-needle aspiration biopsy (FNAB), and vacuum-assisted biopsy (VAB), each designed for specific clinical scenarios and the varying characteristics of the lesions. Biopsy needles are preferred because they provide diagnostic results with less discomfort for the patient and require less time for both the procedure and recovery compared to surgical biopsies.

The needle breast biopsy procedure segment accounted for the largest market share in 2024.

Based on procedures, the breast biopsy devices market can be broadly categorized into three types: needle breast biopsy, open surgical breast biopsy, and liquid breast biopsy. The growth of the needle breast biopsy segment is driven by several key factors. These include rising breast cancer rates, a greater emphasis on early and accurate diagnosis, and an increasing preference among patients for minimally invasive procedures. Advancements in technology, particularly in image guidance and needle design, have enhanced the accuracy of needle breast biopsies while minimizing discomfort and inconvenience. This has made the procedure more acceptable and feasible for patients. Furthermore, the establishment of breast cancer screening programs, more favorable reimbursement policies, and heightened awareness of women's health issues are also contributing to market growth. Additionally, the preference for outpatient care and the growing interest in cost-effective diagnostic options have led to broader acceptance of needle breast biopsies across various healthcare settings.

The liquid biopsy segment is projected to register the highest CAGR during the forecast period.

The breast biopsy devices market is primarily categorized into three main techniques: image-guided biopsy, liquid biopsy, and other methods. The liquid biopsy segment is experiencing growth due to the increasing demand for non-invasive, accurate, and real-time cancer diagnostic solutions. Liquid biopsy processes detect circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the blood, making them less invasive than traditional tissue biopsies. This allows for earlier diagnoses, better tracking of treatment responses, and effective monitoring for recurrence or progression of the disease. Several factors are driving the growth of the liquid biopsy market, including the rising incidence of breast cancer, the advancement of precision (or personalized) medicine, and improvements in molecular diagnostic technologies, particularly through next-generation sequencing (NGS) and digital PCR. The increasing clinical utility and routine application of liquid biopsies, along with a growing awareness of their benefits and supportive regulatory policies, are further promoting the global adoption of these technologies.

The early cancer screening segment dominated the market in 2024.

The breast biopsy market can be broadly categorized based on its applications into four main areas: early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. Early cancer screening holds the largest market share as it plays a crucial role in reducing mortality rates and improving treatment outcomes by detecting cancer at the earliest and most treatable stage. The rising incidence of cancer globally, particularly among vulnerable and aging populations, has increased the need for effective illness monitoring. Consequently, advancements in technology will serve as a significant driver for early and proactive health monitoring and diagnosis.

Asia Pacific is expected to register a significant growth rate in the market during the forecast period.

The breast biopsy market is experiencing the highest growth in the Asia Pacific region due to several converging factors. These include an increasing incidence of breast cancer, the development of healthcare infrastructure, and greater awareness of the importance of early cancer detection. Countries such as China, India, and Japan are making significant investments in interventional and diagnostic imaging, which is creating a demand for advanced biopsy technologies. Additionally, government support, improved access to medical care in rural areas, and the expansion of global medical device companies promoting their products in emerging markets are driving this adoption. Furthermore, the region's large population and rising healthcare spending are key drivers of its double-digit market growth.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level Executives (27%), Director-level Executives (18%), and Other Designations (55%)
• By Region: North America (50%), Europe (20%), Asia Pacific (15%), Latin America (10%), and the Middle East & Africa (5%)

Prominent players in this market are Hologic Inc. (US), Danaher Corporation (US), Argon Medical Devices (US), Merit Medical Systems (US), Menarini-Silicon Biosystems (Italy), Varian Medical Systems, Inc. (Germany), Planmed Oy (Finland), Sterylab S.R.L (Italy), Biocept, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Germany), and Exact Sciences Corporation (US).

Research Coverage

• The report studies the breast biopsy devices market by product, procedure, application, end user, and region.
• The report analyzes factors affecting market growth (drivers, restraints, opportunities, and challenges).
• The report evaluates the market opportunities and challenges for stakeholders and details the competitive landscape for market leaders.
• The report studies micromarkets with respect to their growth trends, prospects, and contributions to the global breast biopsy devices market.
• The report forecasts the revenue of market segments with respect to five major regions.

Key Benefits of Buying the Report:

The report is designed to assist both new entrants and established market leaders, as well as smaller companies in the breast biopsy devices sector, in making informed investment decisions. It provides comprehensive data that supports risk evaluation and validated investment strategies. The report features detailed market segmentation based on end users and regional aspects, enabling you to focus on specific segments. Additionally, it offers thorough coverage and analysis of trends, challenges, growth opportunities, and future prospects, ensuring that your decisions are well-informed and considerate of all relevant factors.

The report provides insights into the following pointers:

• Analysis of key drivers (ongoing innovations in biopsy needle designs and liquid biopsy technologies), restraints (high costs associated with advanced biopsy equipment and imaging technologies and stringent regulatory approval procedures), opportunities (technological advancements in imaging technology), and challenges (accuracy and reliability of certain biopsy procedures), influencing the growth of the breast biopsy devices market.
• Product Development/Innovation: Detailed insights into upcoming technologies, R&D activities, and new product & service launches in the breast biopsy devices market.
• Market Diversification: Exhaustive information about untapped geographies, new products, recent developments, and investments in the breast biopsy devices market.
• Market Development: Comprehensive information about lucrative markets-the report analyzes the breast biopsy devices market across varied regions.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Hologic Inc. (US), Danaher Corporation (US), Argon Medical Devices (US), Merit Medical Systems (US), Menarini-Silicon Biosystems (Italy), Varian Medical Systems, Inc. (Germany), Planmed Oy (Finland), Sterylab S.R.L (Italy), QIAGEN (Germany), and Biocept, Inc. (US), among others

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STUDY LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources of secondary data
    • 2.1.1.2 Objectives of secondary research
    • 2.1.1.3 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key objectives of primary research
    • 2.1.2.3 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH (REVENUE SHARE ANALYSIS)
    • 2.2.1.1 Company revenue estimation approach
    • 2.2.1.2 Customer-based market estimation
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ASSESSMENT
• 2.5 STUDY ASSUMPTIONS
  • 2.5.1 MARKET ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 BREAST BIOPSY DEVICES MARKET OVERVIEW
• 4.2 BREAST BIOPSY DEVICES MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
• 4.3 EUROPE: BREAST BIOPSY DEVICES MARKET, BY REGION AND APPLICATION, 2024
• 4.4 GEOGRAPHIC SNAPSHOT OF BREAST BIOPSY DEVICES MARKET

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing incidence of breast cancer
    • 5.2.1.2 Expansion of private diagnostic chains and imaging centers
    • 5.2.1.3 Increasing demand for minimally invasive and non-invasive procedures
    • 5.2.1.4 Growing awareness regarding early detection of breast cancer
    • 5.2.1.5 Improved reimbursement scenario
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of liquid biopsy tests
    • 5.2.2.2 Stringent regulatory approval procedures
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Technological advancements
    • 5.2.3.2 Growing collaboration and financial support from public and private sectors
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Shortage of skilled professionals
• 5.3 REGULATORY ANALYSIS
  • 5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
  • 5.3.2 REGULATORY LANDSCAPE
    • 5.3.2.1 North America
      • 5.3.2.1.1 US
      • 5.3.2.1.2 Canada
    • 5.3.2.2 Europe
    • 5.3.2.3 Asia Pacific
      • 5.3.2.3.1 Japan
      • 5.3.2.3.2 China
      • 5.3.2.3.3 India
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
  • 5.5.1 PROMINENT COMPANIES
  • 5.5.2 SMALL & MEDIUM-SIZED ENTERPRISES
  • 5.5.3 END USERS
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Ultrasound
    • 5.7.1.2 Mammography-guided stereotactic biopsy
    • 5.7.1.3 MRI
    • 5.7.1.4 Contrast-enhanced mammography (CEM) guidance
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 Gamma-guided biopsy systems
    • 5.7.2.2 Molecular breast imaging (MBI)-guided biopsy
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 Surgical oncology technologies
    • 5.7.3.2 Cryoablation and other minimally invasive ablation technologies
• 5.8 TRADE ANALYSIS
  • 5.8.1 IMPORT DATA
  • 5.8.2 EXPORT DATA
• 5.9 PATENT ANALYSIS
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 THREAT OF NEW ENTRANTS
  • 5.10.2 THREAT OF SUBSTITUTES
  • 5.10.3 BARGAINING POWER OF SUPPLIERS
  • 5.10.4 BARGAINING POWER OF BUYERS
  • 5.10.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.11 PRICING ANALYSIS
  • 5.11.1 AVERAGE SELLING PRICE TREND OF BREAST BIOPSY DEVICES, BY REGION
  • 5.11.2 AVERAGE SELLING PRICE OF BREAST BIOPSY DEVICES, BY APPLICATION
• 5.12 CASE STUDY ANALYSIS
  • 5.12.1 CASE STUDY 1: PET-GUIDED BREAST BIOPSY
  • 5.12.2 CASE STUDY 2: EARLY-STAGE BREAST CANCER AMID COVID PANDEMIC
  • 5.12.3 CASE STUDY 3: SAMPLING MULTIPLE SMALL LESIONS IN DENSE BREAST TISSUE
• 5.13 KEY CONFERENCES & EVENTS, 2025-2026
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS
  • 5.14.2 BUYING CRITERIA
• 5.15 IMPACT OF 2025 US TARIFF ON BREAST BIOPSY DEVICES MARKET
  • 5.15.1 INTRODUCTION
  • 5.15.2 KEY TARIFF RATES
  • 5.15.3 PRICE IMPACT ANALYSIS
  • 5.15.4 IMPACT ON COUNTRY/REGION
    • 5.15.4.1 US
    • 5.15.4.2 Europe
    • 5.15.4.3 Asia Pacific
  • 5.15.5 IMPACT ON END-USE INDUSTRIES
• 5.16 IMPACT OF GENERATIVE AI/AI ON BREAST BIOPSY DEVICES MARKET
• 5.17 INVESTMENT & FUNDING SCENARIO

6 BREAST BIOPSY DEVICES MARKET, BY PROCEDURE

• 6.1 INTRODUCTION
• 6.2 NEEDLE BREAST BIOPSY
  • 6.2.1 CORE NEEDLE BIOPSY
    • 6.2.1.1 Procedural advantages of guidance system-based biopsy to drive revenue growth
  • 6.2.2 VACUUM-ASSISTED BIOPSY (VAB)
    • 6.2.2.1 High diagnostic specificity and accuracy of technique to boost demand
  • 6.2.3 FINE NEEDLE ASPIRATION BIOPSY (FNAB)
    • 6.2.3.1 Drawbacks associated with procedure to limit market growth
• 6.3 OPEN SURGICAL BREAST BIOPSY
  • 6.3.1 EXCISIONAL BIOPSY
    • 6.3.1.1 Risk of post-operative complications to hinder market growth
  • 6.3.2 INCISIONAL BIOPSY
    • 6.3.2.1 Longer recovery period associated with incisional biopsy to restrict growth
• 6.4 LIQUID BREAST BIOPSY
  • 6.4.1 CIRCULATING TUMOR CELLS
    • 6.4.1.1 Ability to provide important information on molecular properties of breast tumors to boost market
  • 6.4.2 CIRCULATING TUMOR DNA (CTDNA)
    • 6.4.2.1 Low concentrations of ctDNA to make screening for clinically relevant mutations challenging
  • 6.4.3 OTHER BIOMARKERS

7 BREAST BIOPSY DEVICES MARKET, BY PRODUCT

• 7.1 INTRODUCTION
• 7.2 BIOPSY NEEDLES
  • 7.2.1 CORE NEEDLES
    • 7.2.1.1 Early detection through core needle biopsy to boost growth
  • 7.2.2 FINE ASPIRATION NEEDLES
    • 7.2.2.1 Accurate clinical decisions for early cancer diagnosis to drive demand for fine aspiration needles
  • 7.2.3 VACUUM-ASSISTED BIOPSY NEEDLES
    • 7.2.3.1 Enhanced accuracy with vacuum-assisted tissue sampling to drive adoption
• 7.3 BIOPSY EQUIPMENT
  • 7.3.1 CORE BIOPSY EQUIPMENT
    • 7.3.1.1 Ability to streamline breast diagnosis with core biopsy technology to boost demand
  • 7.3.2 VACUUM-ASSISTED BIOPSY EQUIPMENT
    • 7.3.2.1 Advantages of VAB in breast biopsy to drive market growth
• 7.4 GUIDANCE SYSTEMS
  • 7.4.1 MAMMOGRAPHY-GUIDED STEREOTACTIC BIOPSY
    • 7.4.1.1 Advantages of technique to boost adoption in coming years
  • 7.4.2 ULTRASOUND-GUIDED BIOPSY
    • 7.4.2.1 Ability to create fine-grained pictures of breasts to drive growth
  • 7.4.3 MRI-GUIDED BIOPSY
    • 7.4.3.1 High cost and low specificity to affect demand
• 7.5 BIOPSY TABLES
  • 7.5.1 GROWING USE OF BIOPSY TABLES TO PERFORM STEREOTACTIC BIOPSY PROCEDURES TO FAVOR MARKET GROWTH
• 7.6 ASSAY KITS
  • 7.6.1 PRODUCT APPROVALS AND LAUNCHES TO DRIVE SEGMENTAL GROWTH
• 7.7 LIQUID BIOPSY INSTRUMENTS
  • 7.7.1 ONGOING RESEARCH AND CLINICAL TRIALS TO DELIVER NOVEL SOLUTIONS IN MARKET
• 7.8 LOCALIZATION WIRES
  • 7.8.1 WIDE USAGE OF LOCALIZATION WIRES TO LOCATE BREAST ABNORMALITIES AND LUMPS TO BOOST MARKET
• 7.9 OTHER PRODUCTS

8 BREAST BIOPSY MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 EARLY CANCER SCREENING
  • 8.2.1 GROWING AWARENESS ABOUT EARLY CANCER DETECTION TO DRIVE SEGMENT GROWTH
• 8.3 THERAPY SELECTION
  • 8.3.1 ABILITY OF PERSONALIZED THERAPY SELECTION TO ENHANCE TREATMENT EFFICACY TO DRIVE DEMAND
• 8.4 TREATMENT MONITORING
  • 8.4.1 GROWING POPULARITY OF REAL-TIME TREATMENT MONITORING TO BOOST MARKET
• 8.5 RECURRENCE MONITORING
  • 8.5.1 UNMET CLINICAL NEEDS TO CREATE OPPORTUNITIES FOR PLAYERS IN MARKET

9 BREAST BIOPSY DEVICES MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS & CLINICS
  • 9.2.1 RISING DEMAND FOR QUICK AND ACCURATE DIAGNOSIS TO BOOST MARKET
• 9.3 IMAGING CLINICS & DIAGNOSTIC CENTERS
  • 9.3.1 RISING NUMBER OF PRIVATE IMAGING CENTERS TO CONTRIBUTE TO MARKET GROWTH
• 9.4 BREAST CARE CENTERS
  • 9.4.1 INCREASING POPULARITY OF BREAST CARE CENTERS IN DEVELOPED COUNTRIES TO BOOST MARKET

10 BREAST BIOPSY DEVICES MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 US to dominate North America breast biopsy devices market during forecast period
  • 10.2.3 CANADA
    • 10.2.3.1 Surge in incidence of breast cancer and favorable government guidelines to support market growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Favorable changes in reimbursement scenario to fuel adoption of technologically advanced products in Germany
  • 10.3.3 UK
    • 10.3.3.1 Initiatives by public & private organizations to increase awareness about breast cancer to drive growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Rising geriatric population to support market growth
  • 10.3.5 ITALY
    • 10.3.5.1 Evolving regulatory scenario for breast biopsy to boost market
  • 10.3.6 SPAIN
    • 10.3.6.1 Increased funding scenario to propel market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Increasing patient pool and government initiatives for healthcare development to fuel market growth
  • 10.4.3 JAPAN
    • 10.4.3.1 Presence of universal healthcare reimbursement scenario and rising breast cancer cases
  • 10.4.4 INDIA
    • 10.4.4.1 Government initiatives to improve female health to drive market growth in India
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Rising research investments and awareness campaigns to support market growth
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Rising R&D and promising clinical trials in country to positively impact market growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Key market in Latin America owing to modernization of healthcare facilities
  • 10.5.3 MEXICO
    • 10.5.3.1 Availability of advanced care and increasing awareness programs to fuel market growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH IN MEA REGION
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.6.3 GCC COUNTRIES
    • 10.6.3.1 Growing healthcare infrastructure to fuel market growth
  • 10.6.4 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
• 11.3 REVENUE ANALYSIS, 2020-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (2024)
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Region footprint
    • 11.5.5.3 Product footprint
    • 11.5.5.4 Procedure footprint
    • 11.5.5.5 Application footprint
    • 11.5.5.6 End-user footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES (2024)
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.6.5.1 Detailed list of key startups/SMEs
    • 11.6.5.2 Competitive benchmarking of startup/SME players, by region
    • 11.6.5.3 Competitive benchmarking of startup/SME players, product
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
  • 11.7.1 FINANCIAL METRICS
  • 11.7.2 COMPANY VALUATION
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 THIS SEGMENT INCLUDES THE GROWTH STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE BREAST BIOPSY DEVICES MARKET BETWEEN JANUARY 2020 AND MAY 2025.
  • 11.9.2 PRODUCT LAUNCHES & APPROVALS
  • 11.9.3 DEALS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 HOLOGIC, INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
      • 12.1.1.2.1 Deals
    • 12.1.1.3 MnM view
      • 12.1.1.3.1 Key strengths
      • 12.1.1.3.2 Strategic choices
      • 12.1.1.3.3 Weaknesses & competitive threats
  • 12.1.2 DANAHER CORPORATION
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches & approvals
      • 12.1.2.3.2 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 BECTON, DICKINSON AND COMPANY
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 MnM View
      • 12.1.3.3.1 Key strengths
      • 12.1.3.3.2 Strategic choices
      • 12.1.3.3.3 Weaknesses & competitive threats
  • 12.1.4 ARGON MEDICAL
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches & approvals
      • 12.1.4.3.2 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses & competitive threats
  • 12.1.5 QIAGEN
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 MERIT MEDICAL SYSTEMS
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches & approvals
      • 12.1.6.3.2 Deals
  • 12.1.7 MENARINI SILICON BIOSYSTEMS SPA
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product launches & approvals
      • 12.1.7.3.2 Deals
  • 12.1.8 GUARDANT HEALTH, INC.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product launches & approvals
      • 12.1.8.3.2 Deals
      • 12.1.8.3.3 Other developments
  • 12.1.9 NEOGENOMICS LABORATORIES, INC.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches & approvals
      • 12.1.9.3.2 Deals
  • 12.1.10 STERYLAB S.R.L
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
  • 12.1.11 BIOCEPT, INC.
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
  • 12.1.12 BIO-RAD LABORATORIES, INC.
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Product launches & approvals
  • 12.1.13 F. HOFFMANN-LA ROCHE LTD.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
  • 12.1.14 EXACT SCIENCES CORPORATION
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Deals
  • 12.1.15 SYSMEX INOSTICS (A SUBSIDIARY OF SYSMEX CORPORATION)
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
    • 12.1.15.3 Recent developments
      • 12.1.15.3.1 Deals
  • 12.1.16 THERMO FISHER SCIENTIFIC
    • 12.1.16.1 Business overview
    • 12.1.16.2 Products offered
    • 12.1.16.3 Recent developments
      • 12.1.16.3.1 Deals
  • 12.1.17 FUJIFILM HOLDINGS CORPORATION
    • 12.1.17.1 Business overview
    • 12.1.17.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 CARDIFF ONCOLOGY INC.
  • 12.2.2 MYRIAD GENETICS, INC.
  • 12.2.3 ILLUMINA, INC.
  • 12.2.4 FLUXION BIOSCIENCES, INC.
  • 12.2.5 INRAD, INC.
  • 12.2.6 IZI MEDICAL PRODUCTS
  • 12.2.7 REMINGTON MEDICAL INC.
  • 12.2.8 CP MEDICAL

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS